Onychomycosis Therapies: Strategies to Improve Efficacy

Dermatologic Clinics

Volumn 24, Issue 3, 2006, Pages 381-386

  Gupta, Aditya K ^a,b   Tu, Linh Q ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE;

DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FAT CONTENT; FOOD DRUG INTERACTION; FOOT CARE; HUMAN; INFECTION PREVENTION; NAIL; ONYCHOMYCOSIS; PATIENT CODING; PATIENT EDUCATION; PRIORITY JOURNAL; RELAPSE; REVIEW; STOMACH PH; TREATMENT FAILURE; TREATMENT PLANNING;

ANTIFUNGAL AGENTS; COMBINED MODALITY THERAPY; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; ONYCHOMYCOSIS;

EID: 33745490748     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2006.03.009     Document Type: Review

References (29)

1. Gupta A.K., Jain H.C., Lynde C.W., et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 43 (2000) 244-248
2. Gupta A.K., Kohli Y., and Summerbell R.C. Variation in restriction fragment length polymorphisms among serial isolates from patients with Trichophyton rubrum infection. J Clin Microbiol 39 (2001) 3260-3266
3. Gupta A.K., and Ryder J.E. How to improve cure rates for the management of onychomycosis. Dermatol Clin 21 (2003) 499-505
4. Arrese J.E., and Pierard G.E. Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology 207 (2003) 255-260
5. Epstein E. How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data. Arch Dermatol 134 (1998) 1551-1554
6. Sigurgeirsson B., Paul C., Curran D., et al. Prognostic factors of mycological cure following treatment of onychomycosis with oral antifungal agents. Br J Dermatol 147 (2002) 1241-1243
7. Tosti A., Hay R., and Arenas-Guzman R. Patients at risk of onychomycosis: risk factor identification and active prevention. J Eur Acad Dermatol Venereol 19 Suppl 1 (2005) 13-16
8. Gupta A.K., Lynde C.W., Jain H.C., et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br J Dermatol 136 (1997) 786-789
9. Evans E.G. The rationale for combination therapy. Br J Dermatol 145 Suppl 60 (2001) 9-13
10. Shuster S. Onychomycosis: making sense of the assessment of anti-fungal drugs. Acta Derm Venereol 78 (1998) 1-4
11. Gupta A.K., Cooper E.A., Macdonald P., et al. Utility of inoculum counting (Walshe and English criteria) in clinical diagnosis of onychomycosis caused by nondermatophytic filamentous fungi. J Clin Microbiol 39 (2001) 2115-2121
12. Roberts D.T., and Evans E.G. Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol 138 (1998) 189-190
13. Schmidt L.E., and Dalhoff K. Food-drug interactions. Drugs 62 (2002) 1481-1502
14. Grifulvin V (griseofulvin tablets) [package insert]. Raritan, NJ: Ortho Pharmaceutical Corporation; 1997.
15. Gupta A.K., De Doncker P., Scher R.K., et al. Itraconazole for the treatment of onychomycosis. Int J Dermatol 37 (1998) 303-308
16. Sporanox (itraconazole capsules) [package insert] (2004), Janssen Pharmaceutica, Titusville, NJ
17. Gupta A.K., Konnikov N., Lynde C.W., et al. Onychomycosis: predisposed populations and some predictors of suboptimal response to oral antifungal agents. Eur J Dermatol 9 (1999) 633-638
18. Diflucan (fluconazole tablets) [package insert] (2004), Pfizer, New York
19. Gupta A.K., Ryder J.E., Lynch L.E., et al. The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence. J Drugs Dermatol 4 (2005) 302-308
20. Scher R.K., and Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 149 Suppl 65 (2003) 5-9
21. Gupta A.K., and Daniel C.R. Onychomycosis: strategies to reduce failure and recurrence. Cutis 62 (1998) 189-191
22. Baran R., and Hay R.J. New evidence for the efficacy of combination therapy in onychomycosis. Br J Dermatol 145 Suppl 60 (2001) 1
23. Pierard G.E., Pierard-Franchimont C., and Arrese J.E. The boosted antifungal topical treatment (BATT) for onychomycosis. Med Mycol 38 (2000) 391-392
24. Pierard G.E., Pierard-Franchimont C., and Arrese J.E. The boosted oral antifungal treatment for onychomycosis beyond the regular itraconazole pulse dosing regimen. Dermatology 200 (2000) 185-187
25. Hay R.J. The future of onychomycosis therapy may involve a combination of approaches. Br J Dermatol 145 Suppl 60 (2001) 3-8
26. Baran R., and Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 19 (2005) 21-29
27. Gupta A.K., and Lynch L.E. Management of onychomycosis: examining the role of monotherapy and dual, triple, or quadruple therapies. Cutis 74 (2004) 5-9
28. Olafsson J.H., Sigurgeirsson B., and Baran R. Combination therapy for onychomycosis. Br J Dermatol 149 Suppl 65 (2003) 15-18
29. Warshaw E.M., and St Clair K.R. Prevention of onychomycosis reinfection for patients with complete cure of all 10 toenails: results of a double-blind, placebo-controlled, pilot study of prophylactic miconazole powder 2%. J Am Acad Dermatol 53 (2005) 717-720